Key Points
- Director John Higuchi bought 12,561 Lipocine shares at an average price of $2.16, investing $27,131.76 and increasing his ownership by 6.16% to 216,358 shares.
- Lipocine shares opened at $2.20, with a market capitalization of $18.14 million and a 52-week range of $1.81 to $12.37. The company reported a quarterly loss of $0.32 per share, better than the $0.40 consensus estimate.
- Analyst sentiment remains mixed, resulting in a consensus “Hold” rating and a $4.00 target price; institutional investors own 9.11% of the company.
Lipocine Inc. (NASDAQ:LPCN - Get Free Report) Director John Higuchi acquired 12,561 shares of the firm's stock in a transaction on Monday, September 28th. The shares were bought at an average price of $2.16 per share, for a total transaction of $27,131.76. Following the completion of the transaction, the director owned 216,358 shares of the company's stock, valued at approximately $467,333.28. This trade represents a 6.16% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Lipocine Price Performance
NASDAQ:LPCN opened at $2.20 on Thursday. The firm has a market capitalization of $18.14 million, a price-to-earnings ratio of -1.23 and a beta of 0.47. The business has a 50 day simple moving average of $2.17 and a 200-day simple moving average of $2.77. Lipocine Inc. has a 1 year low of $1.81 and a 1 year high of $12.37.
Lipocine (NASDAQ:LPCN - Get Free Report) last released its earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.08. Lipocine had a negative return on equity of 64.75% and a negative net margin of 755.39%.The firm had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.21 million. As a group, analysts expect that Lipocine Inc. will post -1.54 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Lipocine in a research note on Tuesday, September 22nd. Wall Street Zen raised shares of Lipocine from a "sell" rating to a "hold" rating in a research note on Saturday, July 18th. Weiss Ratings upgraded shares of Lipocine from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, September 24th. Finally, HC Wainwright reissued a "neutral" rating and issued a $4.00 price objective on shares of Lipocine in a research report on Monday, September 21st. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Lipocine currently has a consensus rating of "Hold" and a consensus target price of $4.00.
Check Out Our Latest Analysis on Lipocine
Hedge Funds Weigh In On Lipocine
Several hedge funds have recently bought and sold shares of the business. Seven Fleet Capital Management LP purchased a new position in Lipocine in the 1st quarter worth about $998,000. Stempoint Capital LP purchased a new stake in Lipocine in the 1st quarter valued at about $1,282,000. ADAR1 Capital Management LLC purchased a new stake in Lipocine in the 1st quarter valued at about $185,000. Eversept Partners LP bought a new position in Lipocine in the 1st quarter worth about $2,357,000. Finally, Exome Asset Management LLC bought a new position in Lipocine in the 1st quarter worth about $486,000. Institutional investors own 9.11% of the company's stock.
Lipocine Company Profile
(
Get Free Report)
Lipocine Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, focused on developing oral therapies for conditions that have traditionally been treated with injections or other less convenient formulations. The company uses its proprietary Lip'ral drug-delivery technology to improve the absorption and administration of certain active pharmaceutical ingredients.
Lipocine's lead product, TLANDO (testosterone undecanoate), is an oral testosterone-replacement therapy approved by the U.S.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
